Merck KGaA amps up in gene therapy with $110M viral vector manufacturing boost

Merck KGaA and subsidiary MilliporeSigma are doubling down on their gene therapy bets with a hefty nine-figure investment into expanded viral vector production.

MilliporeSigma will spend $110 million to open a second viral vector facility in Carlsbad, California, to "more than double" its gene therapy manufacturing capacity, the company said Tuesday.